Aerie Pharmaceuticals Inc., of Irvine, Calif., provided further details on the safety profile for Rhopressa (netarsudil ophthalmic solution), a once-daily eye drop in development for lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, showing it has indicated any drug-related systemic effects and has not generated any serious adverse events.